Published • loading... • Updated
MATSON, INC. ANNOUNCES THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR OUTLOOK
AUVELITY sales and expanding prescriptions lifted revenue 52% year over year, while Axsome narrowed its loss and topped Wall Street estimates.
- Axsome Therapeutics reported $260 million in third-quarter 2026 revenue and a narrowed net loss of $12.9 million. This result marks a significant improvement from the prior year’s earnings performance.
- Stronger sales of AUVELITY drove the revenue acceleration, with management citing expanded adoption as a primary factor behind the company’s improved financial results during the quarter.
- Payer coverage remained stable at 89% of total lives, while the company added 8,200 new prescribers to reach a 77,000 total. Primary care emerged as the fastest-growing segment during the quarter.
- Following pipeline progress, the FDA is reviewing the AXS-12 NDA for cataplexy in narcolepsy with a May 1, 2027, target date. Additionally, top-line results for the ENGAGE Phase III trial are expected in Q1 2027.
- Projections show the product could generate at least $8 billion annually, reflecting projected adoption across depression and Alzheimer agitation indications. This potential confirms its role as a cornerstone of the long-term growth strategy.
Insights by Ground AI
187 Articles
187 Articles
AirBoss Reports 3rd Quarter 2026 Results
NEWMARKET, Ontario, Nov. 04, 2026 (GLOBE NEWSWIRE) -- AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) (the “Company” or “AirBoss”) today announced its third quarter 2026 results. The Company will host a conference call and webcast to discuss the results…
·Mississauga, Canada
Read Full Article
Coverage Details
Total News Sources187
Leaning Left27Leaning Right17Center52Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 28%
C 54%
R 18%
Factuality
To view factuality data please Upgrade to Premium
